



## Applied Proteomics Inc. Collaborates with German Cancer Research Center to Discover and Develop New Cancer Diagnostic Tests

---

SAN DIEGO, CA and HEIDELBERG, GERMANY, October 9, 2013

**Applied Proteomics Inc. (API)**, the leading developer of protein-based molecular diagnostics, announces a collaboration with the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ), the largest biomedical research institute in Germany. Under the collaboration, API and DKFZ will advance the discovery and development of new blood tests for colon and pancreatic cancer.

“Both API and the German Cancer Research Center are focused on novel ways to make cancer diagnosis earlier and more precise to save lives and improve treatment options,” said API President and CEO Peter Klemm. “With this collaboration, we will apply our novel diagnostic tools to detect colorectal and advanced adenoma. We will also be leveraging our mass-spec based discovery platform to research and develop additional protein-based diagnostic tools for pancreatic cancer detection.”

“New avenues of more effective early cancer detection and cancer prevention are an important part of improving the quality of medical care, prognosis and quality of life of cancer patients,” said Prof. Dr. Herrmann Brenner, chair of DKFZ’s Division of Clinical Epidemiology and Aging Research. “Patients with a high-risk of colon and pancreatic cancer have a significant unmet need for new diagnostic tests.”

API’s novel molecular diagnostic tools are based on the conversation of the body—the constant dialogue between proteins— that act as the body’s early-warning system for disease. By tapping into this conversation, API measures the current status of the body’s proteome, enabling disease detection at the earliest stages of development.

API’s first product in development is a blood test for pre-cursors to colorectal cancer to help identify high-risk patients for colonoscopy.

### **About DKFZ**

The German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) with its more than 2,500 employees is the largest biomedical research institute in Germany. At DKFZ, more than 1,000 scientists investigate how cancer develops, identify cancer risk factors and endeavor to find new strategies to prevent people from getting cancer. They develop novel approaches to make tumor diagnosis more precise and treatment of



---

cancer patients more successful. DKFZ is located in Heidelberg. For more information, visit [www.dkfz.de](http://www.dkfz.de).

**About Applied Proteomics Inc.**

API is a molecular diagnostics company focused on developing blood-based multiplex protein tests to help physicians more effectively direct patients towards current standard-of-care patient management. API has developed a proteomics platform solution to make protein-based biomarker discovery possible as a replicable, industrial application ready to be applied to multiple health diagnostic problems. The company is currently advancing several internal diagnostic development programs, and is headquartered in San Diego, CA.

For more information about API and its protein-based diagnostics, visit [www.appliedproteomics.com](http://www.appliedproteomics.com).

###

**Media Contact:**

Jessica Yingling, Ph.D.  
Little Dog Communications  
1-858-344-8091  
[jessica@litldog.com](mailto:jessica@litldog.com)